Ultimovacs ASA (FRA:7UM) Debt-to-Asset : 0.01 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Debt-to-Asset?

Ultimovacs ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.16 Mil. Ultimovacs ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.06 Mil. Ultimovacs ASA's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was €18.30 Mil. Ultimovacs ASA's debt to asset for the quarter that ended in Sep. 2024 was 0.01.

Ultimovacs ASA Debt-to-Asset Historical Data

The historical data trend for Ultimovacs ASA's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Debt-to-Asset Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.01

Ultimovacs ASA Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

Competitive Comparison of Ultimovacs ASA's Debt-to-Asset

For the Biotechnology subindustry, Ultimovacs ASA's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ultimovacs ASA's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultimovacs ASA's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Ultimovacs ASA's Debt-to-Asset falls into.

Ultimovacs ASA Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Ultimovacs ASA's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.159	+	0.164)	/	30.34
	=	0.01

Ultimovacs ASA's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.157	+	0.06)	/	18.303
	=	0.01

Ultimovacs ASA (FRA:7UM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Ultimovacs ASA Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultimovacs ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (FRA:7UM) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden ULTI:Norway 7UM:Germany

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ultimovacs ASA Headlines

No Headlines